Evelyn Degenhard

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text

Medicine, Hematology, Oncology +16

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Blood · 2012 · 469 citations · Full text

Medicine, Hematology, Oncology +15

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier et al. · Blood · 2012 · 463 citations

Life Sciences, Hematology, Immunology +17

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Andreas Viardot, Mariele Goebeler, Richard Noppeney et al. · Blood · 2011 · 26 citations

Veterinary Medicine, Oncology, Pharmacotherapy +8

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max S. Topp, Nikola Goekbuget, Peter Kufer et al. · Blood · 2008 · 26 citations

Medicine, Hematology, Oncology +17